MOLN Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 4.63 |
| 52 Week High | CHF 9.50 |
| 52 Week Low | CHF 3.11 |
| Beta | 0.53 |
| 1 Month Change | -5.61% |
| 3 Month Change | 13.08% |
| 1 Year Change | 22.68% |
| 3 Year Change | -74.67% |
| 5 Year Change | -73.20% |
| Change since IPO | -79.35% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate
Sep 10
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?
Jan 09Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17
Shareholder Returns
| MOLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -6.8% | -1.9% | -0.5% |
| 1Y | 22.7% | 91.7% | 2.8% |
Return vs Industry: MOLN underperformed the Swiss Biotechs industry which returned 91.7% over the past year.
Return vs Market: MOLN exceeded the Swiss Market which returned 2.8% over the past year.
Price Volatility
| MOLN volatility | |
|---|---|
| MOLN Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 12.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MOLN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: MOLN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 162 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MOLN fundamental statistics | |
|---|---|
| Market cap | CHF 170.49m |
| Earnings (TTM) | -CHF 62.59m |
| Revenue (TTM) | CHF 6.00m |
28.4x
P/S Ratio-2.7x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLN income statement (TTM) | |
|---|---|
| Revenue | CHF 6.00m |
| Cost of Revenue | CHF 49.97m |
| Gross Profit | -CHF 43.96m |
| Other Expenses | CHF 18.63m |
| Earnings | -CHF 62.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 07, 2025
| Earnings per share (EPS) | -1.70 |
| Gross Margin | -732.47% |
| Net Profit Margin | -1,042.84% |
| Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 03:47 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Molecular Partners AG is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurizio Bernasconi | Bank am Bellevue |
| null null | Credit Suisse |
| Thomas Kaufmann | Credit Suisse |